Ventyx Biosciences, Inc. (NASDAQ:VTYX) Q2 2023 Earnings Call Transcript

Marty Auster: Yes, Bill, I think you hit on a lot of the things that we see and we talk about internally, what we hear from KOLs and folks we engage with in the field. I think it’s a combination of the factors you cited, along with also as you sort of talked around the efficacy there. Sam, on Zeposia, it was in sort of very low double digits. So it wasn’t particularly sort of — it wasn’t groundbreaking or exciting efficacy. It’s perceived as a slower onset of action drug as well, which is better of a fast onset of action, of course, with the active metabolite data that the drug works through. So I think we’ve got some benefits with VTX002 that I think are hopefully more attractive attributes to the market. And obviously, we’ll be watching closely as you and our investors will on how Pfizer’s regulatory outcome and commercial launch goes to the etrasimod later this year.

Sam Slutsky: Thanks.

Operator: Thank you. And at this time, there are no further questions in the queue. So I’d like to turn the floor back over to Dr. Mohan for additional or closing remarks.

Raju Mohan: Great. And thank you all again, all the analysts, all the investors for your continued interest in Ventyx. Hopefully, we will connect with many of you at one of the upcoming conferences we plan to attend in the third quarter. And we’re really excited for the fourth quarter approaches. Looking forward to sharing our Phase 2 top line results with you for both, starting with 002 in UC and then followed by VTX958 in psoriasis. So thank you all once again.

Operator: Thank you. This concludes today’s Ventyx Biosciences second quarter 2023 earnings conference call. Please disconnect your line at this time, and have a wonderful day.